Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Skye issued a press release on June 10, 2024, “announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion (“OE”) in patients with primary open-angle glaucoma “POAG”) or ocular hypertension (“OHT”) did not meet its primary endpoint for lowering intraocular pressure (“IOP”). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027.”
Following this news, Skye’s stock price fell over 8% on June 10, 2024.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
SMCI | Super Micro Computer, Inc. | October 29, 2024 | Join |
ZI | ZoomInfo Technologies Inc. | November 04, 2024 | Join |
WBTN | WEBTOON Entertainment Inc. | November 04, 2024 | Join |
GTLB | GitLab Inc. | November 04, 2024 | Join |
GTLB | GitLab Inc. | November 04, 2024 | Join |
AGEN | Agenus Inc. | November 05, 2024 | Join |
NFE | New Fortress Energy Inc. | November 18, 2024 | Join |
MGX | Metagenomi, Inc. | November 25, 2024 | Join |
BMBL | Bumble Inc. | November 25, 2024 | Join |
UPS | United Parcel Service, Inc. | December 09, 2024 | Join |
EW | Edwards Lifesciences Corporation | December 13, 2024 | Join |
TD | The Toronto-Dominion Bank | December 23, 2024 | Join |